1. Introduction {#s0005}
===============

Microarrays can be most simply defined as a collection of microscopic spots (or features) of biological capture molecules (such as DNA or proteins) spatially arranged in a predefined order on a solid substrate. In DNA microarrays (also known as DNA chips or biochips), each spot contains predefined short (25- to 70-nucleotide) single-stranded DNA oligonucleotides or larger (200- to 800-basepair) double-stranded DNA, which are known as probes. A microarray experiment consists of the hybridisation of a sample of target DNA in solution, whose identity or abundance is being sought, with a typically large number of probes fixed to the substrate. Target DNA molecules are prepared with fluorescent tags, the microarray is exposed to the resulting mixture under conditions that favour hybridisation, and any unbound DNA fragments are washed away. Microarray positions with DNA--DNA hybrids are then detected optically, indicating the components that were present in the starting sample. Each microarray experiment is therefore a large number of hybridisation experiments done in parallel and as such, microarrays can be thought of as 'highly parallel' processors of biological queries. Various microarray methods are available and differ in the type of the probe, the solid support and the methods used for addressing the probe and detecting the target ([@bb0530]). Microarray technologies commonly used for the detection and identification of microbial targets include solid-state microarrays, electronic microarrays and suspension bead microarrays. Details of these technologies, including probe length, number of possible features (or density) and surface chemistry employed, are described below and compared in [Table 1](#t0005){ref-type="table"} . In this chapter, we review the concepts behind each of these microarray technologies and describe clinical applications of microarray analysis for pathogen detection, genotyping and antimicrobial resistance testing in the microbiology laboratory.Table 1Comparison of Microarray TechnologiesTechnologyPrincipleProbe LengthFeaturesSolid SupportReferencesPrintedPre-synthesised probes are deposited onto solid surface and attached by covalent or electrostatic chemistry25--80 base≤ 30,000Glass slide[@bb0280] and [@bb0410]*In situ* synthesised with photolithographic maskProbes are synthesised in parallel directly on solid surface with phosphoramidite protection/deprotection chemistry using mask-directed photolithography20--25 base\> 1,000,000Silicon chip[@bb0055] and [@bb0615]*In situ* synthesised with digital micromirrorProbes are synthesised in parallel directly on solid surface with phosphoramidite protection/deprotection chemistry using maskless photodeprotection with digital micromirror devices60--100 base15,000--\>1,000,000Silicon chip[@bb0710]*In situ* synthesised with inkjetProbes are synthesised in parallel directly on solid surface with phosphoramidite protection/deprotection chemistry using acid-mediated chemical deprotection with inkjet printing60 base15,000--\>1,000,000Glass slide[@bb0310]ElectronicPre-synthesised probes are transported to specific locations on the solid surface by electric field and immobilised by streptavidin-biotin bonding20--30 base400Silicon chip[@bb0720] and [@bb0210]Suspension bead arrayPre-synthesised probes are covalently coupled to solid surface15--100 base≤ 500Polystyrene microspheres[@bb0200] and [@bb0205]

2. Solid-State Microarrays {#s0010}
==========================

Solid-state (also called solid-phase) microarrays, in particular, use rigid, impermeable substrates (such as glass or silicon wafers) as the solid support ([@bb0240], [@bb0590]). The microscopic features, each with thousands of identical probes immobilised to the solid surface, are arranged in an orderly fashion at high density. Solid-state microarrays are the technological descendants of 'dot-blotting' techniques ([@bb0330]), which involved the application of macroscopic spots over porous membranes (i.e. nitrocellulose or gel pads). The introduction of solid substrates was critical to the success of DNA microarrays for high-throughput large-scale biological applications ([@bb0345]). With probes tethered to a solid surface rather than being buried in pores, the rate of hybridisation is significantly increased and the subsequent washing steps are unhampered by diffusion effect. The rigidity of the solid support improves image acquisition and processing by producing sharper images, and high image definition is indispensable to the micron-scale feature sizes achieved on these microarrays.

2.1. Printed Microarrays {#s0015}
------------------------

Printed (spotted) microarrays are built by depositing pre-synthesised probes onto glass slides using fine-pointed pins ([Figure 1](#f0005){ref-type="fig"} ; [@bb0280], [@bb0410]). The probes can be short oligonucleotides, cDNA or PCR products, and the surface attachment chemistry can be either covalent or non-covalent. Covalent attachment requires the addition of an aliphatic amine (NH~2~) group to the 5′-end of the probe. The probes are then attached to the glass from their 5′-end. Non-covalent attachment involves electrostatic attraction between the amine groups on the glass slide and the phosphate group of the probe\'s backbone. Non-covalent interactions are not strong enough to tether short oligonucleotide probes to glass, thus non-covalent attachment is more appropriate for cDNA microarrays.Figure 1Printed microarrays. (A) Pre-synthesised oligonucleotide or DNA probes are spotted onto glass slides using fine-pointed pins. After printing, the probes are chemically fixed to the slide. (B) Samples containing target DNA are processed through extraction, labelling and hybridisation to the microarray. (C) The hybridised microarray is scanned, and the raw images are processed and analysed.

The delivery of probes onto the glass slide is achieved with spotting robots using either contact or non-contact microarray printing. Contact printing technologies have been used since the early days of microarray technology. They are based on pin tools, which are dipped into the sample solution to take up a small volume of sample and then brought in contact with the slide surface to deliver the sample as a small spot. The currently available pins deliver spot volumes in 0.5--12 nl range, resulting in spot diameters from 62.5 to 600 μm. Non-contact printing enables microarray printing without direct contact to the surface. It uses piezoelectric, bubble-generated and micro-solenoid-driven dispensers that work with the same principle as inkjet printers. These systems are capable of dispensing single drops down to a volume of several hundred picolitres.

After the probes are printed, the surface of the array is usually chemically modified (fixed) making the attachment of additional DNA unfeasible. Fixing is desired to avoid non-specific binding of the DNA target from the sample to the glass slide during hybridisation. Post-production modification of the surface to make it more hydrophilic is also common so as to facilitate the mixing of the target DNA during hybridisation.

2.2. *In Situ*-Synthesised Microarrays {#s0020}
--------------------------------------

Probes for very high-density microarrays are synthesised base-by-base and *in situ* on the solid surface of the microarray. The most straightforward method for synthesising oligonucleotides involves adding nucleotides one at a time to the growing end of an oligonucleotide chain. In this method, the sequence of the oligonucleotide chain is dictated by the order in which dNTPs are added to the reaction. For solid-phase *in situ* chemical synthesis of DNA, an alternative chemical oligonucleotide synthesis based on phosphoramidite (protection/deprotection) chemistry is coupled with a solid support containing covalent linker molecules ([@bb0060]). Phosphoramidite building blocks (phosphoramidite nucleosides) derived from chemically protected 2′-deoxynucleosides (dA, dC, dG and dT) are used in phosphoramidite protection/deprotection chemistry. The protection of the amine, phosphate and hydroxyl reactive groups ensures the prevention of unwanted side reactions. For the protection of the exocyclic amino group, standard schemes use a benzoyl group for adenosine and cytidine and an isobutyryl group for guanosine. Thymidine does not have a reactive exocyclic amino group and hence does not need any protection.

The *in situ* synthesis of the oligonucleotide chain using protection/deprotection chemistry consists of reaction cycles, where each cycle of reactions results in the addition of a single base. The base added has a protective group on its 5′-end to prevent the addition of more than one base during each round of synthesis. At the initial stage, the terminal 3′-base is covalently attached to the solid support. Oligonucleotides are synthesised in the 3′- to 5′-direction (as opposed to the 5′- to 3′-direction in DNA replication) by repeating the synthesis cycle, as many times as required until the desired length of DNA is achieved. A protection/deprotection synthesis cycle has the following four conceptual steps:1.*Deprotection*: the protecting group of the 5′-terminal nucleotide is removed, yielding a reactive 5′-hydroxyl (OH) ready to bond with the as yet to be added phosphoramidite.2.*Coupling*: an activated nucleoside phosphoramidite is brought in contact with the support-bound oligonucleotide precursor. The 5′-OH group reacts with the activated phosphoramidite moiety forming a phosphite triester bond. This is an unstable linkage for the oligonucleotide at the end of the coupling reaction and a small fraction of the 5′-OH groups remains unreacted. The fraction of the newly added bases that are actually incorporated into the growing DNA chain is called coupling efficiency. One desired property of a high-yield nucleotide synthesis scheme is a high coupling efficiency.3.*Capping*: the permanent blocking of the unreacted 5′-OH groups by treating with a chemical catalyst mixture.4.*Oxidation*: the phosphite triester bond formed after coupling is unstable under the oligonucleotide synthesis conditions. An oxidation step involves the oxidation of the trivalent phosphite to a more stable pentavalent phosphate.

Different methods used in the deprotection step result in three technologies for *in situ*-synthesised microarrays. These three technologies differ in whether they use photo- or acid-labile protecting groups for 5′-OH group of the nucleoside phosphoramidite and in how they achieve the combinatorial chemistry involved in parallel synthesis of thousands of probes.

### 2.2.1. Photodeprotection using photolithographic mask {#s0025}

In this method, which forms the basis of Affymetrix® GeneChip® technology, light is used to convert the protective group on the 5′-terminal nucleotide into an OH group ([Figure 2](#f0010){ref-type="fig"} ). During each round of synthesis, the selective exposure of specific array locations (features) to light is achieved with a physical chromium mask that allows light to reach only certain areas of the microarray. This technique, known as photolithography, was adapted from the manufacturing of silicon microprocessor chips ([@bb0055], [@bb0615]). Those features exposed to light become active for further synthesis. The microarray surface is then flushed with a solution containing a single type of nucleotide, but the chemical coupling occurs only in those features that have been deprotected. The newly coupled nucleotides also have a protecting group so the process can be repeated with the application of another mask and subsequent flushing of another nucleotide, until all probes have been fully synthesised. Each probe on the microarray requires four masks per round of synthesis. The probes on an Affymetrix GeneChip microarray are 25 nucleotides long, requiring nearly 100 masks per microarray. The photolithographic masks are expensive to produce but once designed and manufactured, they can be reused to make a large number of identical microarrays with high fidelity. Thus, Affymetrix GeneChip technology is well positioned for making large numbers of standardised microarrays.Figure 2*In situ*-synthesised microarray using mask-assisted photolithography. (Top) A lithographic mask is used to transmit or block UV light from chemically protected nucleotides on the microarray surface. (Bottom) Protecting groups (circles) are removed by UV exposure, allowing addition of a single protected nucleotide (square). The cycle is repeated using different masks sequentially to dictate the order of nucleotide sequence in the oligonucleotide probes.

### 2.2.2. Maskless photodeprotection using digital micromirror devices {#s0030}

Maskless photodeprotection is also based on light-directed synthesis but uses a digital micromirror device for selective light exposure of array features ([@bb0710]). This is the method behind the Roche NimbleGen Maskless Array Synthesiser (MAS) technology. A digital micromirror device is a solid-state silicon device with an array of aluminium mirrors that can be computer controlled to direct light to desired locations of the solid microarray surface ([Figure 3](#f0015){ref-type="fig"} ). It effectively creates virtual masks replacing standard photolithographic masks. NimbleGen\'s digital micromirror device is able to pattern up to 786,000 individual pixels of light which enables minimum feature sizes of 17 μm. Since there are no physical masks to produce, the primary expense of the maskless approach is the chemistry. The flexibility of the virtual masks enables production of small batches of high-density microarrays with different array layouts in a matter of days.Figure 3Maskless *in situ*-synthesised microarray using digital micromirrors. Digital micromirror technology is used to create virtual masks for photodeprotection. UV light is directed through the mask image onto the microarray surface to remove the protecting group (circles) and allow addition of a single nucleotide (square). The steps are repeated with different virtual masks to direct the synthesis of the desired oligonucleotides in a selected pattern.

### 2.2.3. Chemical deprotection with inkjet-mediated synthesis {#s0035}

This method underlying Agilent Technologies' microarrays couples chemical acid-mediated deprotection with inkjet printing to deposit 60 basepair oligonucleotides one base at a time on standard glass slides ([@bb0310]). The deprotection of the DMT-protected nucleoside phosphoramidite is achieved with the removal of the DMT with trichloroacetic acid. In the coupling step of the synthesis cycle, the inkjet printer uses tiny nozzles for each monomer and chemical activators to place picolitre drops of reagents in specified locations on the microarray ([Figure 4](#f0020){ref-type="fig"} ).Figure 4*In situ*-synthesised microarray using chemical deprotection with inkjet-mediated synthesis. This method uses acid-mediated deprotection with inkjet printing for oligonucleotide probe synthesis. The printer uses tiny nozzles to deposit picolitre amounts of nucleotides and reagents in specified locations of the microarray. Repeated rounds of printing extend the probe length to 60 nucleotides.

### 2.2.4. Comparison of *in situ* synthesis technologies {#s0040}

Micromirror and inkjet technologies allow computer controlled synthesis of each feature at the time of array production, while photolithography requires physical pre-made masks. This makes the former technologies highly flexible but these technologies are less efficient for making large batches of identical arrays compared to photolithographic masking. Variants of phosphoramidite-based synthesis have different coupling efficiencies. The yield of the desired probes is dependent on the length of the oligonucleotide being synthesised. With low coupling efficiencies and longer probes, eventually the yield of full-length oligos becomes unacceptably low. Photodeprotection and acid-mediated deprotection of dimethoxytrityl protecting group have coupling efficiencies of approximately 95% and 98%, respectively ([@bb9000]). The chemical deprotection used in inkjet-mediated synthesis allows the inkjet technology to be more suitable for high-fidelity synthesis of longer oligonucleotides.

2.3. Electronic Microarrays {#s0045}
---------------------------

The printed and *in situ*-synthesised microarrays rely on passive transport for the hybridisation of nucleic acids. In contrast, electronic microarrays utilise active hybridisation via electric fields to control nucleic acid transport ([Figure 5](#f0025){ref-type="fig"} ). Commercially available as NanoChip® XL by Savyon Diagnostics (formerly NanoChip® 400 from Nanogen, Inc.), the core technology of the microelectronic cartridge uses complementary metal oxide semiconductor technology for the electronic addressing of nucleic acids ([@bb0720]). The cartridge has 12 connectors that control 400 individual test sites. The microarray is generated by transport of negatively charged nucleic acids to specific sites when an electric field is applied to one or more test sites on the microarray ([@bb0210]). The surface of the microarray contains streptavidin, which allows the formation of streptavidin--biotin bonds with biotinylated probes reaching each location through the application of a specific electrical field, thus immobilising the probe onto the surface. The electric field is then removed from the active features, and new test sites can be activated.Figure 5Electronic microarray. (Left) Positive current is applied to specific test sites (pads) to assist movement of negatively charged DNA probes to the activated pads. Probes are attached by streptavidin--biotin binding. The site is deactivated and the current applied to a different pad to localise a new probe. The process is repeated until all of the probes are arrayed. (Right) Samples are extracted, amplified and hybridised to the microarray surface. Target-specific secondary probes and fluorescent detector oligonucleotides are used to measure positive hybridisation reactions.

Once the probes have been hybridised at discrete test sites, the microarray is ready for the application of fluorescently labelled target DNA. Target DNA passively hybridises with the immobilised probes on the microarray or is concentrated electronically ([@bb0045], [@bb0385]). Electronically addressing the capture probe first is the most commonly used assay format, but amplicon first and sandwich assays have also been described ([@bb0225]). If hybridisation occurs between the probe and the target DNA, fluorescent reporters will be present at the positive test site(s) and will be detected when the electronic microarray is scanned and analysed by an imaging instrument using a charge-coupled device (CCD) camera with data collection and analysis software.

3. Suspension Bead Arrays {#s0050}
=========================

Suspension bead microarray technologies are three-dimensional arrays that use microparticles (microspheres or beads) as the solid support for the binding reaction and flow cytometry or CCD imaging for detection of the bead and associated target ([Figure 6](#f0030){ref-type="fig"} ). The particles can be distinguished into subsets by different classification features, such as internally absorbed fluorophores, size or diameter and surface or composition characteristics, and multiplexing is achieved through the unique features of the particle subsets. The xMAP® Technology platform by Luminex® is a bead-based suspension microarray technology commonly used for detection of nucleic acids and utilises polystyrene microspheres that are internally dyed with two or three spectrally distinct fluorochromes ([@bb0195]). Using precise amounts of each of these fluorochromes, an array is created consisting of different bead sets with specific spectral addresses. A specific capture oligonucleotide probe is covalently coupled to the surface of the specific bead sets or bead sets precoupled with unique capture oligonucleotides are commercially available for nucleic acid microarray assay development. The target nucleic acid is captured by hybridisation to the complementary probe sequence and labelled with a reporter molecule (i.e. fluorescent dye) to allow detection and quantitation of the specific binding that has occurred at the particle surface. Multiple readings are made per bead set or target, providing a fluorescent output signal of the hybridisation results.Figure 6Suspension bead array. Microspheres (beads) are internally dyed with different intensities of red and infrared dyes to create 500 beads sets with unique spectral identities. Bead sets coupled with specific oligonucleotide probes are hybridised to amplified targets generated from the starting sample. Hybridised targets are labelled using a fluorescent reporter dye, and the microsphere suspension is analysed by flow cytometry or CCD imaging to identity each bead and quantify the reporter probe-target reaction on the microsphere surface.

A variety of assay chemistries can be used for generating the DNA targets for suspension bead hybridisation, including direct capture, competitive hybridisation and solution-based enzymatic chemistries in combination with universal capture probes ([Figure 7](#f0035){ref-type="fig"} ).Figure 7Suspension bead assay formats. (A) In direct hybridisation, target DNA is amplified and biotin labelled. The amplified products are denatured, hybridised to specific probe-coupled bead sets and labelled with streptavidin-linked fluorescent reporter. (B) In competitive hybridisation, labelled oligonucleotides containing the target sequences compete with target DNA in the test sample for hybridisation to specific probe-coupled bead sets. The sample target DNA concentration is inversely proportional to the bead-associated reporter signal, which decreases as sample concentration increases. (C) Enzymatic assay chemistries (primer extension, oligonucleotide ligation and PCR) are used to identify the target sequences in the sample and incorporate specific capture tag sequences. The targets are hybridised to bead sets bearing complementary anti-TAG probes, and labelled for detection.

3.1. Direct Hybridisation {#s0055}
-------------------------

Direct hybridisation of a labelled PCR-amplified target DNA to bead sets bearing specific oligonucleotide capture probes is a simple and commonly used assay chemistry and typically employs probes of approximately 20 nucleotides in length ([@bb0195], [@bb0205]). The probes are complementary in sequence to the labelled strand of the PCR product and the polymorphic nucleotide (for single-nucleotide discrimination) is located at or near the centre of the probe. The oligo probes are modified with a 5′-terminal amine for covalent attachment to the functional carboxyl group on the microsphere surface and contain a spacer (usually C-12) between the amine and probe sequence to minimise steric hindrance of hybridisation at the microsphere surface. PCR primers are typically designed to amplify 50- to 300-basepair regions of target sequence with one primer of each pair biotinylated at the 5′ end for labelling the target strand of the amplicon. Using a small target DNA minimises the potential for steric hindrance to affect hybridisation efficiency adversely at the bead surface ([@bb0195]).

3.2. Competitive Hybridisation {#s0060}
------------------------------

Competitive hybridisation is similar to direct hybridisation in probe and target design. However, in the competitive assay format, unlabelled double-stranded PCR-amplified targets compete with labelled single-stranded oligonucleotide targets for annealing to the sequence-specific capture probes on the microspheres ([@bb0255]).

3.3. Enzymatic Chemistries with Universal Capture Probes {#s0065}
--------------------------------------------------------

Another approach is to use a sequence-specific enzymatic reaction in solution to identify the target DNA, followed by capture onto a universal probe sequence on the bead surface for detection. This format involves the incorporation of a capture sequence during the enzymatic step that allows hybridisation to a complementary sequence attached to the bead surface. Commonly used enzymatic methods for sequence determination rely on the discriminating ability of DNA polymerases and DNA ligases, and include allele-specific or target-specific primer extension, oligonucleotide ligation, single-base chain extension and target-specific PCR ([@bb0200], [@bb0750], [@bb0855]). These chemistries are used in combination with bead reagents precoupled with universal oligonucleotide capture sequences that are chosen to have identical hybridisation parameters with minimal cross-reactivity ([@bb0485]). This approach takes advantage of the speed of solution-phase hybridisation and permits the universal bead sets to be used in many different assays where new sequences can be targeted by adding the appropriate capture sequence to the target-specific oligonucleotide used in the enzymatic step.

4. Clinical Applications of Microarray Testing {#s0070}
==============================================

The detection and genetic characterisation of microbial pathogens by microarray methods have been developed for several applications in the clinical microbiology laboratory. The large number of microarray probes available in several commercial platforms allows for highly multiplexed assays, enabling detection of a broad range of organisms and/or discrimination of multiple genetic elements within the targeted species ([@bb0530]). At the current time, the clinical utility of microarray methods is primarily limited by our lack of detailed understanding about how genetic changes affect organism phenotype and outcomes of infections. The rapid expansion of knowledge about multigenic virulence and resistance traits will allow for clinically actionable interpretation of complex microarray data and additional uses for this testing in patient care. While other molecular methods such as next-generation sequencing can yield the same or additional genetic data for interpretation, targeted microarray methods will likely continue to be used in conjunction with high-throughput sequencing, as they can provide more rapid or cheaper tests for particular indications ([@bb0700]).

The combination of microbial detection and genotypic characterisation in a single assay is one of the attractions of microarray testing in the clinical laboratory. Probes specific for individual pathogens can be utilised, along with genetic markers such as resistance elements, to provide information enabling early optimisation of therapy. For some pathogens such as *Mycobacterium tuberculosis*, phenotypic susceptibility testing can take days or weeks to complete, and empiric treatment must be initiated in the interim ([@bb0570], [@bb0670]). Often in bacterial infections, phenotypic susceptibility test results are available within 24--48 h, and the utilisation of microarray testing will depend on factors such as turnaround time, cost and the failure rate of empiric antibiotic coverage. It should be noted that the sensitivity may vary for species detection versus resistance markers, so that resistance prediction could be less reliable for organisms present in low titers ([@bb0765]). Guidelines have been developed for validation and implementation of microarrays for diagnosis of infectious disease in clinical laboratories ([@bb0160]).

4.1. Pathogen Detection {#s0075}
-----------------------

Most microarrays detect target organisms based on conserved gene targets that are amplified and labelled prior to hybridisation and detection. Therefore, the spectrum of detection depends on both the number of available probes covering the desired species and the ability to amplify the regions of interest using conserved primers. No single target gene or genetic region will allow for detection of all pathogens of interest, so microarrays will typically target one or more classes of organisms. The most commonly used gene targets are listed in [Table 2](#t0010){ref-type="table"} , and include 16S ribosomal DNA (rDNA) (bacteria), internal transcribed spacers for 18S or 28S rDNA (fungi) and *rpoB* (mycobacteria) ([@bb0020], [@bb0275], [@bb0510]). Because it is not possible to design a primer pair that is completely conserved among all prokaryotic species for any gene target, PCR may be performed using degenerate primers or under conditions that allow for primer mismatches to still amplify the expected product. Therefore, species with lower sequence identity to primer regions can be identified, but require higher numbers of organisms for detection. More distantly related organisms may not be detectable, and the diversity of detectable species can be predicted based on known sequences or determined experimentally ([@bb0020], [@bb0510]).Table 2Conserved Gene Targets Used for Microarray DetectionGeneFunctionOrganism ClassReferences16S rDNAProtein synthesisBacteria, Mycobacteria[@bb0510], [@bb0020] and [@bb0275]23S rDNAProtein synthesisBacteria, Mycobacteria[@bb0860] and [@bb0420]*rpoB*RNA polymeraseBacteria, Mycobacteria[@bb0005] and [@bb0275]*gyrB*TopoisomeraseBacteria, Mycobacteria[@bb0320] and [@bb0250]16S--23S rRNA internal transcribed spacerProtein synthesisBacteria, Mycobacteria[@bb0355] and [@bb0795]*cpn60*ChaperoninBacteria[@bb0505]*parE*TopoisomeraseBacteria[@bb0320]*recA*DNA repairBacteria[@bb0135]*wecE*Lipid synthesisEnterobacteriaceae[@bb0505]*hsp65*ChaperoninMycobacteria[@bb0640]*dnaJ*ChaperoninMycobacteria[@bb0555]IS6110PromoterMycobacteria[@bb0755]*sodA*Superoxide dismutaseMycobacteria[@bb0375]32 kDa proteinSecreted proteinMycobacteria[@bb0715]18S and 28S rRNA internal transcribed spacersProtein synthesisFungi[@bb0430], [@bb0100] and [@bb0405]Genus-specific viral family targetsVariousViruses[@bb0840]

### 4.1.1. Identification of organisms isolated by culture-based methods {#s0080}

Microarrays can be useful for the identification of unusual or difficult to identify organisms isolated by culture-based methods. Arrays are designed for a particular pathogen type, with species diversity dependent on the microarray targets and amplification strategy used. Microarrays can be applied to common bacterial pathogens, but are more often used when alternative techniques such as biochemical tests, MALDI-TOF mass spectrometry or 16S gene sequencing are not available ([@bb0865]).

Bacterial identification by microarray has been demonstrated for potential biothreat organisms, such as *Bacillus anthracis*, where reliable differentiation from environmental *Bacillus* species is necessary ([@bb0095]) and for food or waterborne pathogenic bacteria ([@bb0305], [@bb0505], [@bb0895]). Substantial genotype information can be derived from these isolates at a single-nucleotide polymorphism (SNP) level ([@bb0760]). Comparative genomic arrays can allow for sensitive discrimination of related isolates and detect virulence-associated genes in pathogens such as *Staphylococcus aureus* ([@bb0725], [@bb0830]).

Slow growing and fastidious organisms can be efficiently identified by microarrays, including mycobacteria ([@bb0250], [@bb0770]) and fungi ([@bb0100], [@bb0430]). A commercially available line probe system uses the 16S--23S mycobacterial spacer for identification of 17 mycobacterial species with high sensitivity and specificity ([@bb0525], [@bb0780]). Microarrays have also been applied directly on patient samples to aid diagnosis, where assay sensitivity is a critical factor ([@bb0415]). Microarrays can also be applied to the identification of viruses isolated in culture, using conserved targets within viral families, which can be applied to atypical or highly pathogenic viruses ([@bb0235], [@bb0840]).

### 4.1.2. Identification of organisms in positive blood cultures {#s0085}

The identification of organisms growing in blood cultures and the detection of resistance mechanisms may facilitate earlier and more targeted antimicrobial therapy. This has the potential to improve patient outcomes while reducing the need for the use of broad-spectrum antibiotic therapy. Microarray technology has been successfully applied to positive blood cultures, where the organism concentration is high enough that successful detection can be demonstrated. Molecular diagnostic techniques and MALDI-TOF mass spectrometry can yield similar information 1--3 days sooner than standard biochemical tests, and there are now several commercial assays available for clinical use ([@bb0085], [@bb0390], [@bb0445]).

Microarray targets can include many clinically relevant organisms, or target-specific pathogen types as determined by the initial Gram stain. The differentiation of Gram-positive cocci into virulent *S*. *aureus* versus the much less pathogenic *Staphylococcus epidermidis* can lead to significant treatment changes, and these panels typically contain resistance elements such as *mecA* for staphylococcal methicillin resistance and *vanA* for vancomycin-resistant enterococci ([@bb0585], [@bb0605], [@bb0655]). Gram-negative bacterial microarray panels typically identify *Enterobacteriaceae* species and *Pseudomonas aeruginosa*, and detect resistance mechanisms such as beta-lactamases and carbapenemases ([@bb0740]). The accuracy of these assays in predicting cephalosporin and carbapenemase susceptibility will depend on the extent of the panel targeting various classes of beta-lactamase genes and the local circulating strain epidemiology. Panels can also target fungal pathogens, typically identifying *Candida* species to enable optimised antifungal therapy ([@bb0010], [@bb0860]).

Data are still emerging about the optimal approach to translate blood culture microarray results into improved clinical care. While the presence of resistance elements such as *mecA* and *bla* beta-lactamase gene influence outcomes, host factors such as age and comorbidities are major factors as well ([@bb0635]). It appears that intervention by an infectious disease or pharmacy practitioner is needed to realise maximum benefit from earlier identification and resistance marker results ([@bb0660]). As clinicians become more familiar with these tests and decision algorithms are developed, specialist consultation may become less necessary to achieve their potential improvements in outcomes.

### 4.1.3. Application of microarrays directly to patient samples {#s0090}

#### 4.1.3.1. Respiratory infections {#s0095}

The use of multiplexed respiratory pathogen detection panels has become routine in many clinical laboratories. Several commercial multiplex panels, including microarray assays, are available and have been approved by regulatory agencies. These typically contain a variety of respiratory virus targets and differ in the scope of detection and ability to subtype (i.e. inclusion of human coronaviruses and subtyping of parainfluenza or adenovirus), as well as the workflow and hands-on time required ([@bb0380], [@bb0490]). Comparative studies have shown some differences in assay sensitivities for particular targets, particularly adenovirus and influenza B ([@bb0025], [@bb0625]). Some assays may in addition contain bacterial targets such as *Bordetella pertussis*, *Chlamydophila pneumoniae* and *Mycoplasma pneumoniae*, and they all can be adapted to diagnose lower tract as well as upper tract respiratory infections ([@bb0475], [@bb0650]).

Larger microarray panels allow for the diagnosis of more cases of respiratory infection ([@bb0070], [@bb0460], [@bb0705]), but can be difficult to develop and validate for use in the clinical laboratory. Resequencing microarrays allow for detection of co-infections, strain discrimination and epidemiologic tracking of respiratory pathogens ([@bb0450], [@bb0455]). Microarrays using pan-pathogen detection methods such as random amplification followed by broad-spectrum target hybridisation demonstrate a large amount of diversity in viral flora and have diagnosed atypical infections such as human parainfluenzavirus 4, rubella, measles and influenza C ([@bb0150], [@bb0360], [@bb0685]).

Fungal respiratory infections are an attractive target for microarray testing, since these pathogens can be difficult to grow and some require relatively long incubation periods. Species-specific identification of yeasts, moulds and dimorphic organisms including *Histoplasma capsulatum* and *Coccidioides immitis* can be detected in a single test and correlate with clinical and microbiological disease diagnosis ([@bb0405]). Microarrays can be particularly useful for diagnosis of immunocompromised patients with suspected invasive fungal infection, where detection is difficult by conventional methods ([@bb0730]).

Rapid detection of mycobacterial pathogens can also improve treatment decisions, and commercially available assays have been evaluated for direct patient sample testing, yielding high specificity but lower sensitivity than when compared to conventional culture-based methods ([@bb0775]).

The clinical interpretation of respiratory microarray testing is relatively straightforward in the case of viral detection in a symptomatic patient, although the significance of co-infections is less certain. Rapid molecular methods can be useful to guide therapy for pneumonia based on the type of organism detected and resistance genes present, but clinical trial data have not yet been published ([@bb0215]).

#### 4.1.3.2. Gastrointestinal infections {#s0100}

Conventional methods of identification for gastrointestinal pathogens are typically time-consuming and limited in scope to relatively few organisms. Several different tests are employed (i.e. bacterial culture, microscopy for parasite identification, and viral antigen detection or PCR testing), but additional tests may still be needed to detect less common pathogens. By combining multiple organism types onto a single panel, microarray methods have the potential to simplify testing protocols, while providing high sensitivity and the test panels can include species not commonly tested for by conventional methods ([@bb0325]). Mixed infections may also be detected and information regarding the infecting parasite species or bacterial subspecies can be generated and used for epidemiologic studies ([@bb0495], [@bb0805]). Commercially available microarray tests have been shown to increase the number of pathogens detected compared to conventional methods and may provide a faster turnaround time for bacterial and parasitic pathogens ([@bb0295], [@bb0515], [@bb0560]). Future uses may include identification of the intestinal microbiota associated with certain disease states and manipulation of this through probiotic therapy ([@bb0120]).

#### 4.1.3.3. Bloodstream infections {#s0105}

The full benefit of rapid molecular diagnosis of sepsis requires use of direct patient blood samples to allow for the shortest time to actionable results. These panels can include fastidious organisms that are difficult to diagnose using conventional methods ([@bb0230]). However, many septic patients have less than one bacteria cell per millilitre of blood, and the extraction of large amounts of blood is technically difficult ([@bb0365]). Therefore, the sensitivity of direct bloodstream detection is a limiting factor, but these results can still be useful to guide more rapid treatment decisions ([@bb0315], [@bb0675]). Some molecular panels have been shown to increase the number of detected bacterial infections over culture, assisting the diagnosis in immunocompromised and in patients where antimicrobial therapy has already been initiated ([@bb0090], [@bb0565]).

Several microarray-based assays for the detection of bacteria, yeast and viruses have been described, some with sensitivities of 100% compared to blood culture ([@bb0180], [@bb0680], [@bb0825]). Optimised DNA extraction methods, primer sets and amplification conditions are needed to achieve sensitivities down to 10^1^ bacterial cells per millilitre of whole blood ([@bb0580], [@bb0820]). Microarrays can also be used to interrogate the host transcriptomic profile and generate gene expression patterns that correlate with bacterial sepsis or other inflammatory states ([@bb0745]). However, validated clinical algorithms using direct bloodstream pathogen detection and confirmatory data from large prospective studies demonstrating improvements in clinical outcomes are not yet available.

#### 4.1.3.4. Urinary tract infections {#s0110}

Microarrays have been applied to the direct detection of uropathogens with high sensitivity, but since they are not quantitative, the ability to differentiate a true pathogen in urine containing mixed flora is limited ([@bb0440]). Therefore, most studies have focused on the detection of resistant organisms such as carbapenem-resistant *Enterobacteriaceae* and fluoroquinolone-resistant *Escherichia coli* or nosocomial bacteria such as *P*. *aeruginosa* and *Acinetobacter baumannii* ([@bb0340], [@bb0620], [@bb0875]). Novel approaches including electronic biosensor arrays are in development for rapid detection of uropathogens with minimal sample processing, with the eventual goal of providing point-of-care testing capability ([@bb0400]).

#### 4.1.3.5. Genital tract infections {#s0115}

Detection of sexually transmitted disease pathogens through microarray panels has been described for *Neisseria gonorrhoeae*, *Chlamydia trachomatis* and *Ureaplasma urealyticum* using a multiplex primer-amplification approach ([@bb0105], [@bb0425], [@bb0695]). However, commercial development has focused on human papillomavirus (HPV) detection and genotyping as part of cervical cancer diagnosis and screening. Genotyping is needed to distinguish high-risk HPV types (16 and 18) from other intermediate and low-risk types. Microarrays in a variety of formats have been developed to identify up to 120 known genotypes of HPV infection in cervical cytology and swab specimens ([@bb0015], [@bb0220], [@bb0690]). For this application, detection sensitivity is less important than the ability to discriminate between low-risk patients and those with carcinomas that are likely to progress clinically, which is typically assessed using abnormal histology at cervical intraepithelial neoplasia (CIN) grade 2 + or higher. Most tests have been compared to the Hybrid Capture II assay and show similar or improved analytical sensitivity ([@bb0155], [@bb0595]). Currently, only the real-time PCR-based Cobas HPV assay has been evaluated in a large trial and specifically approved by the U.S. Food and Drug Administration for primary cervical cancer screening, which improved sensitivity from 52% to 88% for CIN2 or greater and from 53% to 92% for CIN3 or greater compared to liquid-based cytology ([@bb0130], [@bb0835]).

#### 4.1.3.6. Skin, soft tissue and joint infections {#s0120}

Detection microarrays are best suited to identify non-commensal pathogens in non-sterile site infections or a wide range of organisms in sterile sites. They have been reported to detect cutaneous mycobacterial infection, and superficial and invasive mycoses ([@bb0100], [@bb0125], [@bb0665]). Profiling of the microbiota of healing wounds shows an association of *Acinetobacter* with wound failure, and enteric-associated flora with successful healing ([@bb0050]). The identification of prosthetic joint infection can be enhanced by molecular techniques such as 16S PCR sequencing, and a microarray-based assay enhances detection in patients previously treated with antibiotics ([@bb0520]).

#### 4.1.3.7. Central nervous system infections {#s0125}

Microarrays have been applied to diagnosis of bacterial meningitis, where they have been demonstrated to detect more cases than conventional methods alone, although methods have not been standardised, and there is potential for false-positives through sample contamination ([@bb0065], [@bb0470], [@bb0630]). Identification and differentiation of the fungal pathogens *Cryptococcus neoformans* and *Cryptococcus gattii* are possible in cerebrospinal fluid, but methods need to be optimised for sensitive detection ([@bb0080]). Organisms which cause viral meningitis and encephalitis can be targeted through viral microarrays with probes for human herpesviruses, measles, mumps and enteroviruses ([@bb0075], [@bb0435]). Specialised microarrays have also been developed for highly pathogenic viruses such as chikungunya, yellow fever, dengue, hantavirus and emerging zoonotic agents ([@bb0840]).

4.2. Pathogen Genotyping {#s0130}
------------------------

### 4.2.1. Bacterial genotyping {#s0135}

A large number of research studies have used microarray methods to determine the presence of virulence factors and other genetic elements in bacteria. These techniques are important in investigating pathogens public health significance such as *Salmonella* and *Legionella*, and for outbreak investigations, for example, a multistate *Listeria* outbreak associated with cantaloupe ([@bb0285], [@bb0290], [@bb0395]). From a clinical diagnostic standpoint, bacterial genotyping is rarely needed. In special circumstances, genotyping can assist investigation of infections in immunodeficient patients, for instance to determine whether an individual with *Streptococcus pneumoniae* infection who has been previously vaccinated has a strain included by the vaccine ([@bb0810]). As we acquire more knowledge about the clinical relevance of certain bacterial genotypes and virulence factors in predicting disease severity, genotyping could become useful to track disease epidemiology and indicate more aggressive treatment for certain strains, such as *Clostridium difficile* ribotype 027 ([@bb0370]).

### 4.2.2. Mycobacterial genotyping {#s0140}

*M*. *tuberculosis* strain typing is important for public health control efforts. PCR-based testing for the presence of variable direct repeat spacer oligonucleotides (spoligotyping) is a widely accepted technique, and has been adopted on microarray platforms as a rapid affordable method ([@bb0165], [@bb0645]). Genome deletions and SNPs are stable in *M*. *tuberculosis* clones, making these potential surveillance methods and approaches to study the pathogenesis of strains with known deletions ([@bb0335], [@bb0480]). Clinical microarrays often will contain markers for antibiotic resistance as well (see [Section 4.3.2](#s0165){ref-type="sec"}).

### 4.2.3. Fungal genotyping {#s0145}

Like bacteria, microarrays have been used to determine strain epidemiology and investigate virulence factors in fungal pathogens ([@bb0030], [@bb0260]). For example, gene expression analysis yielded candidate virulence factors in *C*. *gattii* from outbreak strains ([@bb0575]).

### 4.2.4. Viral genotyping {#s0150}

With the exception of HPV genotyping (described in [Section 4.1.3.5](#s0115){ref-type="sec"}), clinical viral genotyping yields prognostic information that can be used to guide treatment decisions or can be used for epidemiological and research purposes. Microarrays can be targeted to specific viral families or pan-viral using unbiased amplification with hybridisation to conserved sequence regions ([@bb0800]). Hepatitis C virus (HCV) genotyping is important to determine the optimal treatment regimen, and microarray-based methods are commercially available ([@bb0190], [@bb0550], [@bb0600]). Hepatitis B virus (HBV) genotype can influence treatment response, and microarray methods can differentiate the various genotypes ([@bb0270]). For other viruses, microarray assays can generate epidemiological information about circulating strains, including segment origin of influenza A or rotavirus genomes, or typing of emerging viruses ([@bb0265], [@bb0300], [@bb0610]).

4.3. Antimicrobial Resistance Gene Detection {#s0155}
--------------------------------------------

### 4.3.1. Bacterial resistance testing {#s0160}

The ability to accurately predict phenotypic resistance from bacteria genetic makeup depends on having a large panel of resistance markers, along with prediction algorithms for each antibiotic drug or class of drugs. Microarrays are well suited to detect resistance genes and cassettes, notably for beta-lactamases and carbapenemases, and can also detect SNPs associated with drug resistance. The tests have reasonably high sensitivity and specificity for detection of known resistance elements, but often will not differentiate functional from non-functional genes and fail to identify other mutation types, such as porin mutants, that can affect resistance profiles ([@bb0170], [@bb0245], [@bb0545]).

Currently available panels for Gram-negative organisms yield a correlation of approximately 90% for positive microarray results with antimicrobial resistance, but microarray-negative results correlate only about 65% with antimicrobial sensitivity ([@bb0115]). These predictive rates vary per drug class and are generally better for plasmid-mediated resistance elements than for chromosomal mutations. They are well suited for identification of bacterial producing specific extended-spectrum beta-lactamases or carbapenemases for infection control and resistance monitoring ([@bb0540]). Quinolone resistance in *E*. *coli* can be identified with known SNPs in *gyrA*, though correlation with phenotypic resistance has been shown for a limited number of isolates ([@bb0040], [@bb0870]). Microarray targets for genotyping antibiotic resistance from nosocomial Gram-negative pathogens include efflux regulators, DNA gyrase, beta-lactamases, aminoglycoside-modifying enzymes and carbapenemases, with genotype--phenotype correlations of 88% for *P*. *aeruginosa* and \> 95% for selected strains of multidrug-resistant *A*. *baumannii* ([@bb0175], [@bb0815]). Mutations in *Helicobacter pylori* 23S rRNA gene associated with clarithromycin resistance can also be detected by microarray testing ([@bb0145]).

For Gram-positive pathogens such as *S*. *aureus*, microarrays can be used to detect clinically relevant resistance mutations for several antibiotics ([@bb0735]). Correlations between array detection and phenotypic resistance are approximately 90% for penicillin, methicillin, aminoglycoside, macrolide and lincosamide resistance by phenotypic testing ([@bb0900]). Other techniques, such as next-generation sequencing, have a high correlation with microarray methods for detection of bacterial resistance mutations. In general, the current data support the ability of these molecular techniques to detect known resistance mutations, but they have not been prospectively tested with large numbers of clinical isolates from a variety of locations to determine the performance characteristics relative to conventional phenotypic susceptibility testing ([@bb0790]). Assay turnaround time and manual manipulation steps generally have to be reduced for these tests results to be available in a clinically relevant time frame.

### 4.3.2. Mycobacterial resistance testing {#s0165}

Mycobacterial resistance microarray platforms have focused on *M*. *tuberculosis*, the most clinically significant pathogen in this group. Phenotypic testing is delayed due to the organism\'s slow growth, so that molecular techniques can yield rapid detection of resistance mutations, allowing earlier transition to second-line treatment. About 95% of rifampin-resistant strains have certain known point mutations and rearrangements in *rpoB* gene ([@bb0110], [@bb0880]). Approximately 80% of isoniazid-resistant strains have a *katG* mutation and about 20% have *inhA* mutations ([@bb0350], [@bb0850]). Pyrazinamide resistance is associated with mutations in the *pncA* gene, though about 40% of resistant strains have no mutation in this gene ([@bb0185]). Microarray-detected *embB* mutations are found in about 75% of ethambutol-resistant strains ([@bb0535]).

For second-line *M*. *tuberculosis* therapies, mutations in *rpsL* were found associated with streptomycin resistance, though sensitivity was low due to limited microarray gene coverage. The same study found sensitivities for detection of resistance at 100% for rifampin, 90% for isoniazid and 70% for ethambutol ([@bb0465]). Other second-line drugs for which microarrays can yield detection of resistance mutations include fluoroquinolones, kanamycin and capreomycin ([@bb0905]). Other than tuberculosis, a microarray has been developed to detect resistance polymorphisms in *Mycobacterium leprae* ([@bb0500]). Overall, microarray methods for detecting resistance in mycobacterial species are promising, but still require testing of a large number of geographically diverse isolates to determine their ability to guide therapeutic choices.

### 4.3.3. Fungal resistance testing {#s0170}

Several mechanisms of antifungal resistance in yeast have been identified, and many of these involve overexpression of genes encoding for drug targets or efflux pump transporters. Gene expression microarrays can identify genes associated with azole resistance in *Candida albicans* and are useful in identifying specific mutations affecting promoter expression ([@bb0845]). Increased expression of ergosterol biosynthesis genes is important for amphotericin B resistance in *C*. *albicans*, while azole resistance in *Candida glabrata* is associated with upregulation of the *CgPDR1* pleiotropic drug resistance network locus ([@bb0035], [@bb0785]). As more knowledge is gained about the specific mutations causing these upregulations, microarrays can be used to identify strains carrying known resistance mutations.

### 4.3.4. Viral resistance testing {#s0175}

Detection of known resistance mutations in viruses is amenable to microarray testing and can be implemented as a more economical method than full gene sequencing in resource-limited settings. Testing for HIV resistance in protease and reverse transcriptase genes yields \> 95% concordance with sequencing, with a few discrepant cases due to increased sensitivity of microarray over sequencing methods ([@bb0885]). For HBV, microarray targets can accurately identify mutations associated with lamivudine resistance ([@bb0140]). Microarrays designed to detect mutations in the neuraminidase and matrix genes of influenza A can identify these strains with high accuracy ([@bb0890]). As more viral resistance mutations conferring resistance to therapy are discovered, microarrays will offer a cost-effective method to detect them in clinical and epidemiological settings.

Conclusions {#s0180}
===========

Microarrays offer a convenient method for interrogating specific pathogen sequences on scales of tens to hundreds of thousands of oligonucleotide probes. Several technologies and platforms are available, including solid-state, electronic and suspension bead microarrays, each with multiple variations in probe synthesis chemistries, linkage and data collection and analysis formats. Samples are typically amplified using multiplex primer sets, followed by hybridisation, washing and signal detection. Microarrays have been adopted for microbial detection, genotyping and antimicrobial resistance gene detection directly from clinical samples or from isolated organisms. Limits of detection are comparable to other molecular techniques, but still may not be equivalent to large-volume culture techniques such as blood cultures.

Microarray assays are limited by the set of available probe sequences, so they may not detect unusual sequence variants or novel genetic elements of clinical significance. Careful consideration must be taken during assay design and validation to distinguish between closely related species differing in virulence (i.e. *S*. *pneumoniae* vs. viridans *Streptococcus*), and to ensure that relevant circulating strains containing sequence variations are adequately detected and identified. Ideally, probe sets should be updated to reflect changing genotypes and strain epidemiology. The performance of microarray tests needs to be determined for different specimen types or matrices that may be encountered during clinical testing.

Microarray tests are well suited to offer a panel approach to diagnose specific patient presentations, such as respiratory viral infection or infectious diarrhoea. They can also discriminate between clinical isolates by genotype, which can be useful for tracking epidemiology and for outbreak investigations. As more information has become available regarding specific genes and pathways involved in antimicrobial resistance, we are beginning to be able to predict susceptibility patterns based on sequence interrogation for particular organisms. With further advances in automated microarray processing methods and genotype--phenotype prediction algorithms, these tests will become useful as an adjunct or replacement for conventional susceptibility testing, allowing for more rapid selection of targeted therapy for infectious disease.
